Autoimmune hepatitis

Adolescent Medicine Clinics

Volumn 15, Issue 1, 2004, Pages 131-143

  Li, Ding You ^a   Schwarz, Kathleen B ^b  

^a UNIVERSITY OF MISSOURI KANSAS CITY SCHOOL OF MEDICINE   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; AUTOANTIGEN; AZATHIOPRINE; BUDESONIDE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; CYCLOSPORIN A; CYTOCHROME P450; CYTOKINE; METHOTREXATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; PROTEIN DERIVATIVE; TSUKUBAENOLIDE;

ADOLESCENT; ALLELE; ANTIGEN PRESENTING CELL; AUTOIMMUNE DISEASE; BONE MARROW SUPPRESSION; CELLULAR IMMUNITY; CLINICAL FEATURE; CLINICAL TRIAL; CYTOKINE PRODUCTION; DIAGNOSTIC PROCEDURE; DISEASE COURSE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG HYPERSENSITIVITY; DRUG TOLERABILITY; ENVIRONMENTAL FACTOR; GASTROINTESTINAL SYMPTOM; GENETIC PREDISPOSITION; HEPATITIS; HISTOLOGY; HUMAN; IMMUNE RESPONSE; INCIDENCE; LABORATORY TEST; LIVER TRANSPLANTATION; MEDICAL ASSESSMENT; PANCREATITIS; PATHOGENESIS; PATIENT COMPLIANCE; POSTOPERATIVE COMPLICATION; PROGNOSIS; RASH; RECURRENT DISEASE; REVIEW; SCORING SYSTEM; SEX DIFFERENCE; SIDE EFFECT; STATISTICAL SIGNIFICANCE; SURVIVAL RATE; T LYMPHOCYTE ACTIVATION; TREATMENT OUTCOME; TREATMENT PLANNING; TREATMENT WITHDRAWAL; VEIN OCCLUSION;

EID: 3142750511     PISSN: 15473368     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.admecli.2003.11.009     Document Type: Review

References (61)

1. Czaja AJ, Freese DK. Diagnosis and treatment of autoimmune hepatitis. Hepatology 2002;36:479-97.
2. Johnson PJ, McFarlane IG. Meeting report: International Autoimmune Hepatitis Group. Hepatology 1993;18:998-1005.
3. Gregorio GV, Portmann B, Reid F, et al. Autoimmune hepatitis in childhood: a 20-year experience. Hepatology 1997;25:541-7.
4. Alvarez F, Berg PA, Bianchi FB, et al. International Autoimmune Hepatitis Group Report: Review of criteria for diagnosis of autoimmune hepatitis. J Hepatol 1999;31:929-38.
5. Homberg JC, Abuaf N, Bernard O, et al. Chronic active hepatitis associated with antiliver/kidney microsome antibody type 1: a second type of "autoimmune" hepatitis. Hepatology 1987;7:1333-9.
6. Baeres M, Herkel J, Czaja AJ, et al. Establishment of standardized SLA/LP immunoassays: specificity for autoimmune hepatitis, worldwide occurrence, and clinical characteristics. Gut 2002;51:259-64.
7. Kanzler S, Weidemann C, Gerken G, et al. Clinical significance of autoantibodies to soluble liver antigen in autoimmune hepatitis. J Hepatol 1999;31:635-40.
8. Kerkar N, Hadzic N, Davies ET, et al. De-novo autoimmune hepatitis after liver transplantation. Lancet 1998;351:409-13.
9. Donaldson PT, Doherty DG, Hayllar KM, et al. Susceptibility to autoimmune chronic active hepatitis: human leukocyte antigens DR4 and A1 - B8-DR3 are independent risk factors. Hepatology 1991;13:701-6.
10. Strettell MD, Donaldson PT, Thomson LJ, et al. Allelic basis for HLA-encoded susceptibility to type 1 autoimmune hepatitis. Gastroenterology 1997;112:2028-35.
11. Czaja AJ, Doherty DG, Donaldson PT. Genetic bases of autoimmune hepatitis. Dig Dis Sci 2002;47:2139-50.
12. Huppertz HI, Treichel U, Gassel AM, et al. Autoimmune hepatitis following hepatitis A virus infection. J Hepatol 1995;23:204-8.
13. Vento S, Garofano T, Di Perri G, et al. Identification of hepatitis A virus as a trigger for autoimmune chronic hepatitis type 1 in susceptible individuals. Lancet 1991;337:1183-7.
14. Laskus T, Slusarczyk J. Autoimmune chronic active hepatitis developing after acute type B hepatitis. Dig Dis Sci 1989;34:1294-7.
15. Vento S, Cainelli F, Renzini C, et al. Autoimmune hepatitis type 2 induced by HCV and persisting after viral clearance. Lancet 1997;350:1298-9.
16. Vento S, Guella L, Mirandola F, et al. Epstein-Barr virus as a trigger for autoimmune hepatitis in susceptible individuals. Lancet 1995;346:608-9.
17. Robertson DA, Zhang SL, Guy EC, et al. Persistent measles virus genome in autoimmune chronic active hepatitis. Lancet 1987;2:9-11.
18. Alvarez F. Autoimmune hepatitis. In: Suchy F, Sokol RJ, Balistreri WF, editors. Liver disease in children. 2nd edition. Philadephia: Lippincott Williams & Wilkins; 2001. p. 429-41.
19. Czaja AJ. Understanding the pathogenesis of autoimmune hepatitis. Am J Gastroenterol 2001;96:1224-31.
20. Gueguen M, Boniface O, Bernard O, et al. Identification of the main epitope on human cytochrome P450 IID6 recognized by anti-liver kidney microsome antibody. J Autoimmun 1991;4: 607-15.
21. Manns MP, Griffin KJ, Sullivan KF, et al. LKM-1 autoantibodies recognize a short linear sequence in P450IID6, a cytochrome P-450 monooxygenase. J Clin Invest 1991;88:1370-8.
22. Yamamoto AM, Cresteil D, Boniface O, et al. Identification and analysis of cytochrome P450IID6 antigenic sites recognized by anti-liver-kidney microsome type-1 antibodies (LKM1). Eur J Immunol 1993;23:1105-11.
23. Muratori L, Parola M, Ripalti A, et al. Liver/kidney microsomal antibody type 1 targets CYP2D6 on hepatocyte plasma membrane. Gut 2000;46:553-61.
24. Lapierre P, Hajoui O, Homberg JC, et al. Formiminotransferase cyclodeaminase is an organ-specific autoantigen recognized by sera of patients with autoimmune hepatitis. Gastroenterology 1999;116:643-9.
25. Wies I, Brunner S, Henninger J, et al. Identification of target antigen for SLA/LP autoantibodies in autoimmune hepatitis. Lancet 2000;355:1510-5.
26. Yachida M, Kurokohchi K, Arima K, et al. Increased bcl-2 expression in lymphocytes and its association with hepatocellular damage in patients with autoimmune hepatitis. Clin Exp Immunol 1999;116:140-5.
27. Krawitt EL. Autoimmune hepatitis. N Engl J Med 1996;334:897-903.
28. El-Shabrawi M, Wilkinson ML, Portmann B, et al. Primary sclerosing cholangitis in childhood. Gastroenterology 1987;92:1226-35.
29. Cassani F, Cataleta M, Valentini P, et al. Serum autoantibodies in chronic hepatitis C: comparison with autoimmune hepatitis and impact on the disease profile. Hepatology 1997;26:561-6.
30. Bortolotti F, Vajro P, Balli F, et al. Non-organ specific autoantibodies in children with chronic hepatitis C. J Hepatol 1996;25:614-20.
31. Ma Y, Peakman M, Lobo-Yeo A, et al. Differences in immune recognition of cytochrome P4502D6 by liver kidney microsomal (LKM) antibody in autoimmune hepatitis and chronic hepatitis C virus infection. Clin Exp Immunol 1994;97:94-9.
32. Cook GC, Mulligan R, Sherlock S. Controlled prospective trial of corticosteroid therapy in active chronic hepatitis. Q J Med 1971;40:159-85.
33. Murray-Lyon IM, Stern RB, Williams R. Controlled trial of prednisone and azathioprine in active chronic hepatitis. Lancet 1973;1:735-7.
34. Soloway RD, Summerskill WH, Baggenstoss AH, et al. Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis. Gastroenterology 1972;63:820-33.
35. Lennard L. Clinical implications of thiopurine methyltransferase: optimization of drug dosage and potential drug interaction. Therap Drug Monit 1998;20:527-31.
36. Yates CR, Krynetski EY, Loennechen T, et al. Molecular diagnosis of thiopurine S-methyltransferase deficiency: genetic basis for azathioprine and mercaptopurine intolerance. Ann Intern Med 1997;126:608-14.
37. Maggiore G, Bernard O, Hadchouel M, et al. Treatment of autoimmune chronic active hepatitis in childhood. J Pediatr 1984;104:839-44.
38. Maggiore G, Veber F, Bernard O. Autoimmune hepatitis associated with anti-actin antibodies in children and adolescents. J Pediatr Gastroenterol Nutr 1993;17:376-81.
39. Yachha SK, Srivastava A, Chetri K, et al. Autoimmune liver disease in children. J Gastroenterol Hepatol 2001;16:674-7.
40. Czaja AJ, Davis GL, Ludwig J, et al. Complete resolution of inflammatory activity following corticosteroid treatment of HbsAg-negative chronic active hepatitis. Hepatology 1984;4: 622-7.
41. Alvarez F, Ciocca M, Canero-Velasco C, et al. Short-term cyclosporine induces a remission of autoimmune hepatitis in children. J Hepatol 1999;30:222-7.
42. Mistilis SP, Skyring AP, Blackburn CRB. Natural history of active chronic hepatitis. I. Clinical features, course, diagnostic criteria, morbidity, mortality, and survival. Australas Ann Med 1968;17:214-23.
43. Debray D, Maggiore G, Girardet JP, et al. Efficacy of cyclosporine A in children with type 2 autoimmune hepatitis. J Pediatr 1999;135:111-4.
44. Van Thiel DH, Wright H, Carroll P, et al. A potential new treatment for autoimmune chronic active hepatitis: results of an open-label preliminary trial. Am J Gastroenterol 1995;90:771-6.
45. Richardson PD, James PD, Ryder SD. Mycophenolate mofetil for maintenance of remission in autoimmune hepatitis in patients resistant to or intolerant of azathioprine. J Hepatol 2000;33:371-5.
46. Danielsson A, Prytz H. Oral budesonide for treatment of autoimmune chronic active hepatitis. Aliment Pharmacol Ther 1994;8:585-90.
47. Czaja AJ, Lindor KD. Failure of budesonide in a pilot study of treatment-dependent autoimmune hepatitis. Gastroenterology 2000;119:1312-6.
48. Kanzler S, Gerken G, Dienes HP, et al. Cyclophosphamide as alternative immunosuppressive therapy for autoimmune hepatitis - report of three cases. Z Gastroenterol 1997;35:571-8.
49. Burak KW, Urbanski SJ, Swain MG. Successful treatment of refractory type one autoimmune hepatitis with methotrexate. J Hepatol 1998;29:990-3.
50. Ahmed M, Mutimer D, Hathaway M, et al. Liver transplantation for autoimmune hepatitis: a 12-year experience. Transplant Proc 1997;29:496.
51. Gonzalez-Koch A, Czaja AJ, Carpenter HA, et al. Recurrent autoimmune hepatitis after orthotopic liver transplantation. Liver Transpl 2001;7:302-10.
52. Ratziu V, Samuel D, Sebagh M, et al. Long-term follow-up after liver transplantation for autoimmune hepatitis: evidence of recurrence of primary disease. J Hepatol 1999;30:131-41.
53. Sanchez-Urdazpal L, Czaja AJ, van Hoek B, et al. Prognostic features and role of liver transplantation in severe corticosteroid-treated autoimmune chronic active hepatitis. Hepatology 1992;15:215-21.
54. Saadah OI, Smith AL, Hardikar W. Long-term outcome of autoimmune hepatitis in children. J Gastroenterol Hepatol 2001;16:1297-302.
55. Bahar RJ, Yanni GS, Martin MG, et al. Orthotopic liver transplantation for autoimmune hepatitis and cryptogenic chronic hepatitis in children. Transplantation 2001;72:829-33.
56. Molmenti EP, Netto GJ, Murray NG, et al. Incidence and recurrence of autoimmune/alloimmune hepatitis in liver transplant recipients. Liver Transpl 2002;8:519-26.
57. Andries S, Casamayou L, Sempoux C, et al. Posttransplant immune hepatitis in pediatric liver transplant recipients: incidence and maintenance therapy with azathioprine. Transplantation 2001;72:267-72.
58. Gupta P, Hart J, Millis JM, et al. De novo hepatitis with autoimmune antibodies and atypical histology. A rare cause of late graft dysfunction after pediatric liver transplantation. Transplantation 2001;71:664-8.
59. Hernandez HM, Kovarik P, Whitington PF, et al. Autoimmune hepatitis as a late complication of liver transplantation. J Pediatr Gastroenterol Nutr 2001;32:131-6.
60. Spada M, Bertani A, Sonzogni A, et al. A cause of late graft dysfunction after liver transplantation in children: de novo autoimmune hepatitis. Transplant Proc 2001;33:1747-8.
61. Salcedo M, Vaquero J, Banares R, et al. Response to steroids in de novo autoimmune hepatitis after liver transplantation. Hepatology 2002;35:349-56.